Please assess the completion status of the following clinical trial:

Trial Title: Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be eligible if they meet the following criteria:~* male or female,~* age 25-70 years,~* BMI 26-65,~* type 2 diabetic,~* weight stable for 3 months,~* status post laparoscopic adjustable gastric banding (LAGB) for at least 1 year,~* hemoglobin a1c 7-10%;~* on any diabetic regimen including insulin except for thiazolidinedione use in the past 6 months.~Exclusion Criteria:~Subjects will be excluded if they meet any of the following criteria:~* prior history of pancreatitis,~* prior history of gastroparesis,~* glomerular filtration rate (GFR) \< 50,~* history of thyroid cancer/multiple endocrine neoplasia/thyroid nodules/medullary thyroid cancer,~* history of cholelithiasis,~* history of hyperoxaluria or calcium oxalate nephrolithiasis,~* abnormal AST,~* ALT elevation,~* current or past history of liver disease,~* history of Roux-en-y gastric bypass or gastric sleeve or any other bariatric procedure other than LAGB,~* type 1 diabetes,~* any gastrointestinal disease causing malabsorption (including but not limited to inflammatory bowel disease, celiac sprue),~* prior history of Orlistat or incretin therapy use in past 3 months,~* unwilling or unable to complete scheduled testing,~* thiazolidinedione use within past 6 months,~* any serious and/or unstable medical, psychiatric, or other condition(s) that prevents the patient from providing informed consent or complying with the study.~Patients who have had organ transplantation are on chronic anticoagulation, pregnant or have A1C values \> 10% will also be excluded.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide only (Type: ACTIVE_COMPARATOR): None
- Orlistat only (Type: ACTIVE_COMPARATOR): None
- Liraglutide + Orlistat (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).